"Wenn Sie unter Erkrankungen der Lunge oder Bronchien leiden, mit Schlafstörungen oder Krebs leben, sind wir für Sie da. Dazu umfasst die Klinik für Innere Medizin II folgende Schwerpunktabteilungen: • Lungen- und Bronchialheilkunde • Beatmungsmedizin • Hämatologie und Onkologie • Schlafmedizin • Palliativmedizin In unserem MVZ (Medizinisches Versorgungszentrum) bieten wir Ihnen folgende Spezialsprechstunden an: • Pneumologische Spezialambulanz • Hämatologisch-onkologische Spezialambulanz Als KV-Ermächtigungsambulanz bieten wir Ihnen folgende Spezialsprechstunde an: • Spezialambulanz für Schlafmedizin"

During the past decade, Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 4 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II" #1 collaborator was "InterMune Deutschland GmbH" with 1 trials as a collaborator and "Jazz Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II" are "Non-Small Cell Lung Cancer" (3 trials), "Idiopathic Pulmonary Fibrosis" (1 trials), "Non-Small-Cell Lung" (1 trials), "Non-Squamous Non-Small Cell Lung Cancer" (1 trials) and "Small Cell Lung Carcinoma" (1 trials). Many other conditions were trialed in "Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II" in a lesser frequency.

Most popular intervention types in "Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (3 trials), "Carboplatin" (3 trials), "Docetaxel" (2 trials) and "Etoposide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".